24314 Investors following Sun Pharma. Share this News with them.
0
Like this story, share it with millions of investors on M3
Sun Pharma launches generic Ethyol
Sun Pharmaceutical Industries announced that it has commercially launched generic Amifostine for injection 500mg, which is therapeutically equivalent to MedImmune’s Ethyol®
Sun Pharmaceutical Industries Ltd. announced today that it has commercially launched generic Amifostine for injection 500mg, which is therapeutically equivalent to MedImmune's Ethyol®. Sun Pharma's product is being sold in the United States by its marketing partner Caraco Pharmaceutical Laboratories. Sun Pharma had received a USFDA approval for this earlier in Mar 2008. Ethyol® has annual sales of approximately USD 80 million in the US.
Sun Pharma, being the first-to-file an ANDA for generic Ethyol® with a para IV certification, has a 180-day marketing exclusivity.
Ethyol® is covered under 3 patents - '471 (July 31, 2012), '731 (July 31, 2012) and '409 (Dec 8, 2017). This ANDA was filed with para IV certification against all the patents. Medimmune filed a suit in the District Court of Maryland and the case is under litigation.
|
Budget: 2008, 2009, 2010, 2011, 2012 |
Intuit Money Manager |
RBI Credit Policy | Union Budget | Budget 2012
| Economic Survey
| Railway Budget
| Financial Glossary
|
Message Board |
Moneybhai |
Connect.in.com |
Business Yellow Pages |
India's Premiere Technology Guide | History India
| Up Polls | Latest News
| Mitt Romney | Bharti Airtel | BSE Sensex | Uninor | Iran | EGoM | Aviation | Thomas Cook | Mahindra and Mahindra Limited | Temasek Holdings 
